Literature DB >> 11850065

Ontogenetic development of the G protein-mediated adenylyl cyclase signalling in rat brain.

Ivanna Ihnatovych1, Jiri Novotny, Renata Haugvicova, Lenka Bourova, Pavel Mares, Petr Svoboda.   

Abstract

Maturation of the brain adenylyl cyclase (AC) signalling system was investigated in the developing rat cortex, thalamus and hippocampus. Expression of AC type II, IV and VI measured by Western blot dramatically increased in all tested brain regions during the first 3 weeks after birth and these levels were maintained in adulthood. AC type I did not change during ontogenesis. In parallel, AC enzyme activities were determined in order to obtain the functional correlates to the preceding structural (immunoblot) analyses of trimeric G proteins [Ihnatovych et al., Dev. Brain Res. (2002) in press]. Surprisingly, basal, manganese-, fluoride-, forskolin- and GTP-stimulated adenylyl cyclase developed similarly. The relatively low enzyme activities, which were determined at birth, progressively increased (about four times) to a clear maximum around postnatal day PD 12. This was followed by a progressive regression to adulthood so that activity of AC at PD 90 was comparable with the low neonatal level. The peak of AC activities at PD 12 was detected in all tested brain regions. Stimulatory (isoproterenol) effect on basal AC activity as well as inhibitory (baclofen) effect on forskolin-stimulated AC activity were unchanged between PD 12 and PD 90. Thus, comparison of results of the structural and functional analyses of adenylyl cyclase signalling system revealed a clear dissociation between the increase in the amount protein of various AC isoforms and the decrease of total G-protein mediated enzyme activities between PD 12 and adulthood. As none of the complex changes in trimeric G protein levels can explain this difference, the future research has to be oriented to identification of potential negative regulators of AC in the course of brain development. Among these, the newly discovered group of GTPase activating proteins, RGS, appears to be of primary importance because these proteins represent potent negative regulators of any G protein-mediated signalling in brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850065     DOI: 10.1016/s0165-3806(01)00323-6

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  6 in total

1.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

Review 2.  Regulation of recombinant and native hyperpolarization-activated cation channels.

Authors:  Samuel G A Frère; Mira Kuisle; Anita Lüthi
Journal:  Mol Neurobiol       Date:  2004-12       Impact factor: 5.590

3.  Adenylyl cyclases: expression in the developing rat thalamus and their role in absence epilepsy.

Authors:  Petra Ehling; Tatyana Kanyshkova; Arnd Baumann; Peter Landgraf; Sven G Meuth; Hans-Christian Pape; Thomas Budde
Journal:  J Mol Neurosci       Date:  2012-04-25       Impact factor: 3.444

4.  Pacemaker channels in mouse thalamocortical neurones are regulated by distinct pathways of cAMP synthesis.

Authors:  Samuel G A Frère; Anita Lüthi
Journal:  J Physiol       Date:  2004-01-01       Impact factor: 5.182

Review 5.  Molecular and cellular mechanisms of the age-dependency of opioid analgesia and tolerance.

Authors:  Jing Zhao; Xin Xin; Guo-xi Xie; Pamela Pierce Palmer; Yu-guang Huang
Journal:  Mol Pain       Date:  2012-05-21       Impact factor: 3.395

6.  Respiratory syncytial virus induces β2-adrenergic receptor dysfunction in human airway smooth muscle cells.

Authors:  Terri J Harford; Fariba Rezaee; Manveen K Gupta; Vladimir Bokun; Sathyamangla V Naga Prasad; Giovanni Piedimonte
Journal:  Sci Signal       Date:  2021-06-01       Impact factor: 8.192

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.